<DOC>
	<DOC>NCT00191880</DOC>
	<brief_summary>Open-label trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 years with Attention- Deficit/Hyperactivity Disorder</brief_summary>
	<brief_title>Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients must have ADHD, be psychotropic medication naive and be outpatients who are at least 8 years of age and not more than 10 years of age at Visit 1 (that is, not yet reached their 11 birthday) so that all year testing will be completed before the child reaches age 12. Patients with current or past history of Bipolar I or II disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, conduct disorder, seizure disorder or serious suicidal risk are excluded</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>